
United Therapeutics Shifts Focus To Tyvaso DPI Amidst Generic Threat (NASDAQ:UTHR)
At a Glance United Therapeutics’ (NASDAQ:UTHR) Q2 performance underscores robust financials with a notable 27.7% YoY revenue increase, fueling investor optimism. On the clinical